Lupin Manufacturing Solutions (LMS), a wholly owned subsidiary of global pharmaceutical company Lupin Limited, has entered a long-term strategic alliance with PolyPeptide Group AG, a specialised contract development and manufacturing organisation (CDMO) for peptide-based active pharmaceutical ingredients. The partnership is designed to strengthen and scale the global supply chain for peptide materials, addressing rising demand, particularly for therapies targeting metabolic diseases.
Under the alliance, the two companies will expand sourcing options and fortify peptide supply chains, integrate procurement and supply planning, and work to ensure consistent quality, reliability and superior service on a global scale. The collaboration aims to enhance supply chain resilience, improve operational efficiency and accelerate readiness for the rapidly expanding global peptides market. This includes advancing next-generation peptide therapeutics, with a focus on metabolics and other chronic conditions.
The partnership reinforces LMS’s position as a leading CDMO supplier of peptide materials serving both innovator and generic pharmaceutical markets, while bolstering PolyPeptide’s role as a trusted contract partner in the peptide API space. It reflects both companies’ commitment to building secure, agile and future-ready manufacturing and distribution pathways for peptide-based therapies.
LMS leverages Lupin’s scientific and regulatory expertise, offering integrated solutions from early development through commercial manufacturing. PolyPeptide operates a global network of GMP-certified facilities in Europe, the United States and India, serving pharma and biotech customers with peptide and oligonucleotide APIs.
Also Read